NCT05848843 is a Phase 1 clinical trial of Durvalumab in Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05848843?

NCT05848843 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05848843?

Interventions in NCT05848843: Durvalumab, Adagrasib.

What condition does NCT05848843 study?

NCT05848843 studies Lung Cancer, Gastro-intestinal Cancer.

Is NCT05848843 still recruiting?

NCT05848843 is currently withdrawn. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT05848843

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Withdrawn Phase 1 Last updated 23 January 2024

What this trial tests

Phase 1 trial testing Durvalumab in Lung Cancer. Withdrawn.

Timeline

25 April 2023

Primary endpoint
16 January 2024

16 January 2024

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	25 April 2023
Primary completion	16 January 2024
Estimated completion	16 January 2024
Sites	1 location across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Adagrasib (ADAGRASIB) — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Gastro-intestinal Cancer — all drugs for Gastro-intestinal Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or Gastro-intestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

KRAS G12C inhibitor combination therapies: current evidence and challenge.
Miyashita H, Kato S, Hong DS. · · 2024 · cited 39× · PMID 38756650 · DOI 10.3389/fonc.2024.1380584
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G, Pillozzi S, Antonuzzo L. · · 2024 · cited 35× · PMID 38381540 · DOI 10.1158/0008-5472.can-23-3325
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies.
Linehan A, O'Reilly M, McDermott R, O'Kane GM. · · 2024 · cited 24× · PMID 38576709 · DOI 10.3389/fmed.2024.1369136
Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.
Ma J, Fu S, Tan J, Han Y, et al · · 2025 · cited 5× · PMID 40485603 · DOI 10.1002/advs.202502714
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With <i>KRAS</i><sup>G12C</sup>-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.
Luo J, Florez N, Donnelly A, Lou Y, et al · · 2024 · cited 4× · PMID 38579193 · DOI 10.1200/po.23.00644
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu S, Ma J, Cai C, Tan J, et al · · 2025 · cited 3× · PMID 40611261 · DOI 10.1186/s13046-025-03444-1
Targeting KRAS in colorectal cancer (Review).
Zhang M, Wu D, Tang Y, Zhang L, et al · · 2025 · cited 1× · PMID 40692745 · DOI 10.3892/mco.2025.2873
Adagrasib in the treatment of colorectal cancer.
Haddad SF, Bouferraa Y, Nair KG. · · 2025 · cited 1× · PMID 40619745 · DOI 10.1080/14796694.2025.2524311

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05848843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05848843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing